Home The Word Brain | My Amedeo FAQ Privacy About | ||||||||||
The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al. |
Prostate Cancer |
Free Subscription
3 Anticancer Res |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Prostate Cancer is free of charge.
Association Between Acute Kidney Injury and the Trendelenburg Position Angle
During Robot-assisted Radical Prostatectomy.
Anticancer Res. 2024;44:1767-1772.
PubMed
Abstract available
The Role of Adipocytokines and their Receptors in Prostate Cancer: Adiponectin
May Protect Against Progression.
Anticancer Res. 2024;44:1369-1376.
PubMed
Abstract available
Machine-learning Algorithm-based Risk Prediction and Screening-detected Prostate
Cancer in A Benign Prostate Hyperplasia Cohort.
Anticancer Res. 2024;44:1683-1693.
PubMed
Abstract available
Interaction of patient age and high-grade prostate cancer on targeted biopsies of
MRI suspicious lesions.
BJU Int. 2024 Mar 27. doi: 10.1111/bju.16341.
PubMed
Abstract available
Minimally invasive cytoreductive radical prostatectomy, exploring the safety and
feasibility of a single-port or multi-port robotic platform.
BMC Urol. 2024;24:72.
PubMed
Abstract available
Elucidating the need for prostate cancer risk calculators in conjunction with
mpMRI in initial risk assessment before prostate biopsy at a tertiary prostate
cancer center.
BMC Urol. 2024;24:71.
PubMed
Abstract available
Extended pelvic lymph node dissection during robotic prostatectomy: antegrade
versus retrograde technique.
BMC Urol. 2024;24:64.
PubMed
Abstract available
A practical guide for assessing and managing cardiovascular risk during
androgen-deprivation therapy in patients with prostate cancer.
Cancer. 2024 Mar 26. doi: 10.1002/cncr.35285.
PubMed
Abstract available
High-dose vitamin D to attenuate bone loss in patients with prostate cancer on
androgen deprivation therapy: A phase 2 RCT.
Cancer. 2024 Mar 23. doi: 10.1002/cncr.35275.
PubMed
Abstract available
m6A modification promotes EMT and metastasis of castration-resistant prostate
cancer by upregulating NFIB.
Cancer Res. 2024 Mar 27. doi: 10.1158/0008-5472.CAN-23-1954.
PubMed
Abstract available
A phase I trial of enzalutamide plus selective glucocorticoid receptor modulator
relacorilant in patients with metastatic castration resistant prostate cancer.
Clin Cancer Res. 2024 Mar 27. doi: 10.1158/1078-0432.CCR-23-3636.
PubMed
Abstract available
MRI in-bore biopsy following MRI/US fusion-guided biopsy in patients with
persistent suspicion of clinically significant prostate cancer.
Eur J Radiol. 2024;175:111436.
PubMed
Abstract available
Active surveillance of prostate cancer: MRI and beyond.
Eur Radiol. 2024 Mar 28. doi: 10.1007/s00330-024-10717.
PubMed
Re: First-in-human Evaluation of a Prostate-specific Membrane Antigen-targeted
Near-infrared Fluorescent Small Molecule for Fluorescence-based Identification of
Prostate Cancer in Patients with High-risk Prostate Cancer Undergoing
Robotic-assisted Pro
Eur Urol. 2024 Mar 22:S0302-2838(24)02205-X. doi: 10.1016/j.eururo.2024.
PubMed
Oligometastatic Recurrent Prostate Cancer: Whether To Intensify Treatment or Not.
Eur Urol. 2024 Mar 22:S0302-2838(24)02238-3. doi: 10.1016/j.eururo.2024.
PubMed
Re: Evaluation of Outcomes Following Focal Ablative Therapy for Treatment of
Localised Clinically Significant Prostate Cancer in Patients >70 Years: A
Multi-institute, Multi-energy 15-year Experience.
Eur Urol. 2024 Mar 26:S0302-2838(24)02208-5. doi: 10.1016/j.eururo.2024.
PubMed
Re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the Prevailing
Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol
2024;85:3-7.
Eur Urol. 2024 Mar 26:S0302-2838(24)02233-4. doi: 10.1016/j.eururo.2024.
PubMed
Reply to Richard J. Wassersug, Paul F. Schellhammer, and Erik Wibowo's Letter to
the Editor re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the
Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap
Syndrome. Eur Urol 2024
Eur Urol. 2024 Mar 26:S0302-2838(24)02240-1. doi: 10.1016/j.eururo.2024.
PubMed
Socioeconomic inequality in prostate cancer diagnostics, primary treatment,
rehabilitation, and mortality in Sweden.
Int J Cancer. 2024 Mar 25. doi: 10.1002/ijc.34932.
PubMed
Abstract available
Tissue Contamination Challenges the Credibility of Machine Learning Models in
Real World Digital Pathology.
Mod Pathol. 2024;37:100422.
PubMed
Abstract available
SC912 inhibits AR-V7 activity in castration-resistant prostate cancer by
targeting the androgen receptor N-terminal domain.
Oncogene. 2024 Mar 26. doi: 10.1038/s41388-024-02944.
PubMed
Abstract available
Association of spironolactone use with risk of urinary tract cancer in the
general population: A matched population-based cohort study.
PLoS One. 2024;19:e0300391.
PubMed
Abstract available
Quantification and molecular correlates of tertiary lymphoid structures in
primary prostate cancer.
Prostate. 2024 Mar 27. doi: 10.1002/pros.24684.
PubMed
Abstract available
Clinical validation of circulating GDF15/MIC-1 as a marker of response to
docetaxel and survival in men with metastatic castration-resistant prostate
cancer.
Prostate. 2024 Mar 27. doi: 10.1002/pros.24691.
PubMed
Abstract available
CD44 and CD133 protein expression might serve as a prognostic factor for early
occurrence castration-resistant prostate cancer.
Prostate. 2024 Mar 25. doi: 10.1002/pros.24690.
PubMed
Abstract available
The effect of dose-escalation radiotherapy with simultaneous-integrated-boost on
the use of short-term androgen deprivation therapy in patients with intermediate
risk prostate cancer.
Prostate. 2024 Mar 25. doi: 10.1002/pros.24693.
PubMed
Abstract available
Development of depression in patients using androgen deprivation therapy: A
systemic review and meta-analysis.
Prostate. 2024;84:525-538.
PubMed
Abstract available
Prostate and gut: Any relationship? A narrative review on the available evidence
and putative mechanisms.
Prostate. 2024;84:513-524.
PubMed
Abstract available
Thank you for your interest in scientific medicine.